JMP Securities Maintains Market Outperform on AN2 Therapeutics, Lowers Price Target to $2
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
JMP Securities analyst Roy Buchanan maintains AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform and lowers the price target from $5 to $2.
JMP Securities analyst Roy Buchanan maintains AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform and lowers the price target from $5 to $2.